Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)

Journal of Medical Ethics 38 (3):187-189 (2012)
  Copy   BIBTEX

Abstract

There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,440

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Dependent Rational Providers.K. B. Brothers - 2011 - Journal of Medicine and Philosophy 36 (2):133-147.
Nice and not so nice.J. Harris - 2005 - Journal of Medical Ethics 31 (12):685-688.
Viktor Emil Von gebsattel on the doctor-patient relationship.Jos V. M. Welie - 1995 - Theoretical Medicine and Bioethics 16 (1).

Analytics

Added to PP
2011-09-25

Downloads
41 (#381,426)

6 months
5 (#633,186)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

John Terence Harris
Birkbeck College

Citations of this work

Life in the cloud and freedom of speech.John Harris - 2013 - Journal of Medical Ethics 39 (5):307-311.

Add more citations

References found in this work

No references found.

Add more references